WHAT IS CLAIMED IS:

1. A method for predicting post-operative recurrence of Crohn's disease (CD) in a subject with CD, the method comprising:

(a) detecting the presence or level of one or more serological markers in a sample from the subject, wherein the one or more serological markers includes one or more anti-flagellin antibodies; and

(b) predicting a risk of post-operative recurrence of CD in the subject based upon the presence or level of the one or more serological markers.

2. The method of claim **1**, wherein the one or more serological markers further includes pANCA.

3. The method of claim **1** or **2**, wherein the sample is a pre-operative sample.

4. The method of claim **1** or **2**, wherein the sample is a post-operative sample.

5. The method of any one of claims **1** to **4**, wherein the one or more anti-flagellin antibodies is selected from the group consisting of anti-Fla2 antibodies, anti-FlaX antibodies, anti-CBir1 antibodies, and combinations thereof.

6. The method of any one of claims **1** to **5**, wherein the one or more anti-flagellin antibodies is selected from the group consisting of anti-Fla2 antibodies and anti-FlaX antibodies.

7. The method of any one of claims **1** to **6**, wherein the one or more serological markers further includes ASCA-IgA, ASCA-IgG, anti-OmpC antibodies, CRP, or combinations thereof.

8. The method of any one of claims **1** to **7**, wherein the method further comprises determining the presence or absence of one or more clinical markers.

9. The method of claim **8**, wherein the one or more clinical markers includes active smoking.

10. The method of any one of claims **1** to **9**, wherein the subject is predicted to have an increased risk of post-operative recurrence of CD if the level of the one or more anti-flagellin antibodies is elevated relative to a mean level for healthy individuals and/or relative to a mean level for CD patients.

11. The method of any one of claims **1** to **10**, wherein the subject is predicted to have an increased risk of post-operative recurrence of CD if one or more additional serological markers is present or has an elevated level relative to a mean level for healthy individuals and/or relative to a mean level for CD patients.

12. The method of claim **11**, wherein the one or more additional serological markers includes pANCA, and the sample is pANCA positive.

13. The method of any one of claims **10** to **12**, wherein the method further comprises determining the presence or absence of one or more clinical markers.

14. The method of claim **13**, wherein the one or more clinical markers includes active smoking and the subject is predicted to have an increased risk of post-operative recurrence of CD if the subject is an active smoker.

15. The method of any one of claims **1** to **14**, wherein the subject is predicted to have an increased risk of post-operative recurrence of CD if the level of the one or more anti-flagellin antibodies is at least in the third quartile of the anti-flagellin antibody levels for healthy individuals and/or CD patients.

16. The method of any one of claims **1** to **15**, wherein the post-operative recurrence comprises endoscopic recurrence (ER), histological recurrence (HR), and/or clinical recurrence (CR).

17. The method of any one of claims **1** to **16**, wherein the subject has undergone an intestinal resection.

18. The method of any one of claims **1** to **17**, wherein (b) comprises predicting a risk of post-operative recurrence of CD in the subject by calculating a risk score based upon the presence or level of the one of more serological markers.

~~**19**. The method of claim **18**, wherein the risk score is based upon the presence or level of two or more serological markers.~~

~~**20**. The method of claim **18** or **19**, wherein the risk score is further based upon the presence or absence of one or more clinical markers.~~

~~**21**. The method of claim **20**, wherein the one of more serological markers is a combination of an anti-flagellin antibody and pANCA, and the one or more clinical markers is whether the subject is an active smoker.~~

~~**22**. The method of any one of claims **18** to **21**, wherein a higher risk score is predictive of an increased risk of post-operative recurrence of CD.~~

~~**23**. The method of any one of claims **1** to **22**, wherein the sample is whole blood, serum, or plasma.~~

~~**24**~~1. A method for predicting post-operative recurrence of Crohn's disease (CD) in a subject with CD, the method comprising:

(a) determining the presence of a first risk factor by detecting an elevated level of an anti-flagellin antibody in a sample from the subject;

(b) determining the presence of a second risk factor by detecting the presence of pANCA in the sample;

(c) determining the presence of a third risk factor by determining whether the subject is an active smoker; and

(d) predicting a risk of post-operative recurrence of CD in the subject based upon the presence of the first, second, and third risk factors,

wherein the presence of one of the risk factors is predictive of an increased risk of post-operative recurrence of CD, wherein the presence of two of the risk factors is predictive of a greater risk of post-operative recurrence of CD relative to the presence of one of the risk factors, and wherein the presence of three of the risk factors is predictive of greater risk of post-operative recurrence of CD relative to the presence of two of the risk factors.

~~**25**~~2. The method of claim ~~**24**~~1, wherein the level of the anti-flagellin antibody is elevated if the level is at least in the third quartile of the anti-flagellin antibody level for healthy individuals and/or CD patients.

~~26~~3. The method of claim ~~24~~ 1 or ~~25~~2, wherein the anti-flagellin antibody is selected from the group consisting of an anti-CBir1 antibody, anti-FlaX antibody, anti-Fla2 antibody, and combinations thereof.

~~27~~4. The method of any one of claims ~~24~~ 1 to ~~26~~3, wherein steps (a), (b), and (c) are performed in any order.

~~28~~5. The method of any one of claims ~~24~~ 1 to ~~27~~4, wherein the method further comprises detecting the presence or level of ASCA-IgA, ASCA-IgG, anti-OmpC antibodies, and/or CRP in the sample.

~~29~~6. The method of any one of claims ~~24~~ 1 to ~~28~~5, wherein the post-operative recurrence comprises endoscopic recurrence (ER), histological recurrence (HR), and/or clinical recurrence (CR).

~~30~~7. The method of any one of claims ~~24~~ 1 to ~~29~~6, wherein the subject has undergone an intestinal resection.

~~31~~8. The method of any one of claims ~~24~~ 1 to ~~30~~7, wherein the sample is whole blood, serum, or plasma.

~~32. A method for predicting post-operative recurrence of Crohn's disease (CD) in a subject with CD, the method comprising:~~

~~(a) detecting the presence or level of one or more serological markers in a sample from the subject, wherein the one or more serological markers includes OmpC; and~~

~~(b) predicting a risk of post-operative recurrence of CD in the subject based upon the presence or level of the one or more serological markers.~~

~~33. The method of claim 32, wherein the post-operative recurrence is endoscopic recurrence (ER).~~

~~34. The method of claim 32, wherein the post-operative recurrence is clinical recurrence (CR).~~

~~35. The method of any one of claims 32 to 34, wherein the one or more serological markers further includes ASCA-IgA, ASCA-IgG, pANCA, CRP, or combinations thereof.~~

~~**36**. The method of any one of claims **32** to **35**, wherein the one or more serological markers further includes pANCA.~~

~~**37**. The method of any one of claims **32** to **36**, wherein the one or more serological markers further includes ASCA-IgA.~~

~~**38**. The method of any one of claims **32** to **37**, wherein the sample is a pre-operative sample.~~

~~**39**. The method of any one of claims **32** to **37**, wherein the sample is a post-operative sample.~~

~~**40**. The method of any one of claims **39**, wherein the sample is collected about 3 months to about 12 months after surgery.~~

~~**41**. The method of any one of claims **32** to **40** wherein the method further comprises determining the presence or absence of one or more clinical markers.~~

~~**42**. The method of claim **41**, wherein the one or more clinical markers includes active smoking.~~

9. The method of any one of claims 1 to 8, wherein the sample is a pre-operative sample.

10. The method of any one of claims 1 to 8, wherein the sample is a post-operative sample.

11. The method of any one of claims 1 to 10, wherein a higher risk score is predictive of an increased risk of post-operative recurrence of CD.

12. The method of any one of claims 1 to 11, wherein the sample is collected about 3 months to about 12 months after surgery.